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ILDs represent
parenchyma of the lung
alveolar epithelium 
capillary endothelium
spaces between those structures
perivascular and lymphatic tissues
Involve 
HISTOLOGICALLY ILD 
• INTERSTITIUM
• BASEMENT MEMBRANE OF THE VASCULAR STRUCTURES
• BASEMENT MEMBRANES OF THE EPITHELIAL CELLS
INTRODUCTION
ILD
inflammatory-fibrotic 
Infiltration of the alveolar walls (septa) 
capillary endothelium 
alveolar epithelial 
INTRODUCTION
Fibroblastic proliferation 
Excessive collagen deposition
histologic hallmarks of ILD

interstitial Lung Diseases
progressive exertional dyspnea 
persistent nonproductive cough
Hemoptysis
Wheezing
Chest pain 
interstitial opacities on CXR  
Causes
Idiopathic
Organic
Inorganic
(Pneumoconiosis)
CTD
Drugs
Sarcoidosis
PATHOGENESIS ILDs
nonmalignant 
not infectious agents
injury to fibrosis is not known ?  
mechanisms of repair have common features 
Inflammation and Fibrosis 
inflammation in the air spaces and alveolar walls
Chronic
adjacent portions of the interstitium and vasculature 
interstitial fibrosis  
eventually 
causes 
ILD
Irreversible scarring (fibrosis) 
alveolar walls
Airways
vasculature 
often progressive 
 ventilatory function and gas exchange 

ILDs
>200 known individual diseases 
diffuse parenchymal lung involvement 
Idiopathic
Multiorgan process, CTDs
IDIOPATHIC INTERSTITIAL PNEUMONIAS
IPF
NSIP
RB-ILD
DIP
COP
AIP
Rare IIPs include 
LIP
idiopathic pleuroparechymal fbroelastosis
Unclassifable IIP
Histopathology
predominant inflammation and fibrosis 
predominantly granulomatous reaction
Histopathology
Alveolitis, Interstitial Inflammation, and Fibrosis
Known Cause
Unknown Cause
Granulomatous
Known Cause
Unknown Cause
Histopathology
Alveolitis, Interstitial Inflammation, and Fibrosis
Known Cause
Asbestos
Unknown Cause
IPF
Granulomatous
Known Cause
HP
Unknown Cause
SARCOIDOSIS
CURRENT CLASSIFICATIONS 
• HISTOPATHOLOGY AND CLINICAL SYNDROMES
• IDIOPATHIC INTERSTITIAL PNEUMONITIDES
• GRANULOMATOUS DISORDERS
• CONNECTIVE TISSUE–RELATED ILDS
• DRUG-INDUCED ILDS
• PULMONARY VASCULITIC DISORDERS
• UNKNOWN ORIGIN THAT EXHIBIT WELL-DEFINED SYNDROMES SUCH AS
• PULMONARY LANGERHANS CELL HISTIOCYTOSIS (LCH) 
• LYMPHANGIOLEIOMYOMATOSIS
ILD
Acute phase
Chronic phase
Rarely, recurrent
HISTORY
Duration of Illness 
Acute presentation (days to weeks), unusual  
allergy (drugs, fungi, helminths)  
acute interstitial pneumonia (AIP)  
Hypersensitivity pneumonitis  
confused with atypical pneumonias 
DIAGNOSIS
• SOME ILDS MANIFEST IN AN ACUTE FASHION
• ACUTE PNEUMONITIS DUE TO SYSTEMIC LUPUS ERYTHEMATOSUS
• ACUTE HYPERSENSITIVITY PNEUMONITIS (HP)
• SOME DRUG REACTIONS
• ACUTE INTERSTITIAL PNEUMONIA
• INFECTION OFTEN NEEDS TO BE RULED OUT IN THESE CASES
HISTORY
Duration of Illness 
Subacute presentation (weeks to months) 
Sarcoidosis
drug-induced ILDs
HISTORY
Duration of Illness 
chronic presentation (months to years)
IPF
Sarcoidosis
PLCH 
Pneumoconioses
CTDs
DIAGNOSIS
• DELAYED
• HRCT 
DIAGNOSIS
• MOST ILDS
• IPF
• CHRONIC, PROGRESSIVE SYMPTOMS
•
age, race, and sex 
Most patients with IPF are older than 60 years 
Sarcoidosis
LAM
PLCH
Ages of 20 and 40 years
Gender
LAM / tuberous sclerosis premenopausal women
CTDs  
ILD in RA 
Pneumoconioses
exclusively
women
men
Smoking History usually current or former smokers
Two-thirds to 75%            IPF and familial lung fibrosis 
PLCH 
RB_ ILD 
DIP
DIAGNOSIS
• ENVIRONMENTAL EXPOSURES
• EXPOSURE TO PET BIRDS OR HOT TUBS MAY SUGGEST HP
• OCCUPATIONAL HISTORY
• PNEUMOCONIOSES ASBESTOS AND SILICA EXPOSURE
• BERYLLIOSIS
• GRANULOMATOUS PNEUMONITIS IN INDOOR LIFEGUARDS EXPOSED TO MOLDS
Occupational History 
hypersensitivity pneumonitis 
Pigeon breeder’s disease & workplace (farmer’s lung) 
fever, chills, and an abnormal CXR 
symptoms may reappear 
Past History 
Parasitic infections 
Travel history 
DIAGNOSIS
• THE HISTORY
• RASH, DYSPHAGIA, ARTHRITIS, AND RAYNAUD’S PHENOMENON
• CONNECTIVE TISSUE DISORDER
DIAGNOSIS
• POORLY CONTROLLED ASTHMA
• RADIOGRAPHIC INFILTRATES
• CONSTITUTIONAL SYMPTOMS
• CHURG-STRAUSS SYNDROME
DIAGNOSIS
• SEVERE SINUS DISEASE
• GRANULOMATOSIS WITH POLYANGIITIS GPA (WG) 
DIAGNOSIS
• DRUG-INDUCED ILD 
Diagnosis
Clinician
Radiologist
Pathologist
Approach 
close communication between  
HRCT scanning 
Tissue examination            Thoracoscopic lung biopsy
physical examination 
oxygen desaturation with exertion in early ILD. 
decreased chest expansion during inspection. 
Auscultation Velcro-like crackles at the lung bases. 
clubbing. 
PHYSICAL EXAMINATION 
• SKIN RASHES, 
• ARTHRITIS WITH JOINT DEFORMITIES, 
• RAYNAUD’S PHENOMENON, 
• DYSPHAGIA
• CONNECTIVE TISSUE–RELATED ILD SUCH AS
• DERMATOMYOSITIS OR POLYMYOSITIS, 
• PROGRESSIVE SYSTEMIC SCLEROSIS, 
• MIXED CONNECTIVE TISSUE DISORDER. 
PHYSICAL EXAMINATION 
• EVIDENCE OF RIGHT VENTRICULAR HEART FAILURE
• JUGULAR VEIN DISTENTION
• CARDIAC GALLOP
• LOUD P2 SOUND
• LEG EDEMA
• CHRONIC HYPOXEMIA AND IS OFTEN RELATED TO END-STAGE LUNG DISEASE.
pulmonary hypertension
PHYSICAL EXAMINATION
Tachypnea  
Bibasilar end-inspiratory dry crackles
Scattered late inspiratory high-pitched rhonchi
so-called inspiratory squeaks 
Bronchiolitis
cardiac examination is usually normal 
Pulmonary hypertension and cor pulmonale
Cyanosis and clubbing of the digits 
inflammation 
Clubbing
• EXAMINATION
Clinical FeaturesHISTORY
Onset?
Time? 
Progressive?
PMHx
Smoking
Pets
Exposure in Job/Hobby
Ask specific meds!
If confident ask CTD Sx
After HPCx:
DIAGNOSIS
• LABORATORY STUDIES EOSINOPHILIA
• PULMONARY INFLTRATES AND PERIPHERAL BLOOD EOSINOPHILIA
CHEST RADIOGRAPH
UPPER- AND MID-LEVEL LUNG FIELDS
• SARCOIDOSIS, 
• LCH  
• LYMPHANGIOLEIOMYOMATOSIS
CHEST RADIOGRAPH
LOWER-LEVEL LUNG FIELDS
• IPF, 
• ASBESTOSIS, 
• MANY CONNECTIVE TISSUE–RELATED ILDS
CHEST IMAGING STUDIES
Chest X-Ray ILD
Bibasilar reticular pattern
A nodular 
mixed pattern of alveolar filling and increased reticular 
Honeycombing  
CXR is nonspecific and usually does not allow a specific diagnosis 

PULMONARY FUNCTION TESTING
Spirometry
Most forms of ILD produce a restrictive defect 
TLC
FRC 
RV
PULMONARY FUNCTION TESTING
FEV1
FVC
FEV1/FVC ratio is usually normal or increased 





Diffusing Capacity (DlCO)  
 diffusing capacity of the lung for carbon monoxide
common but nonspecific finding in most ILDs
effacement of the alveolar capillary units 

• ACCUMULATION OF FBROBLASTS
• TIS THICKENED INTERSTITIUM
• POOR OXYGENATION WITH EXERCISE,
• INCREASED LUNG STIﬀNESS EXHIBITED
• DECREASED COMPLIANCE, 
• SMALL LUNG VOLUMES, 
• INCREASED WORK OF BREATHING
Arterial Blood Gas 
Resting ABG may be normal 
significant hypoxemia during exercise or sleep
hypoxemia & respiratory alkalosis
Carbon dioxide (CO2) retention is rare 
usually a manifestation of end-stage disease 
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Small lung volumes
Idiopathic pulmonary fibrosis
Asbestosis
Preserved lung volumes
Sarcoidosis
Hypersensitivity pneumonitis
MIXED PATERNS
• LYMPHANGIOLEIOMYOMATOSIS
• SMALL AIRWAYS ARE NARROWED BY THE PROLIFERATION OF SURROUNDING ABNORMAL SMOOTH
MUSCLE–LIKE CELLS. 
• INCREASED AIRWAY RESISTANCE AND AIRﬂOW OBSTRUCTION. 
• SARCOIDOSIS
• ENDOBRONCHIAL DISEASE WITH DIRECT NARROWING OF THE AIRWAYS CAN OCCUR IN LEADING TO
SIMILAR EﬀECTS
DIAGNOSIS
• CLINICAL AND IMAGING DATA ARE INSUFCIENTLY SPECIFC
• LUNG BIOPSY
• SURGICAL LUNG BIOPSY, A THORACOSCOPIC APPROACH
• TBLB USEFUL FOR
• SARCOIDOSIS
• COP
• HP
MANAGEMENT OF ILD 
• DEPENDS ON THE UNDERLYING CAUSE
• EXPOSURE AVOIDANCE FOR HP, SMOKING-RELATED ILD, AND DRUG-INDUCED ILD. 
• IMMUNOSUPPRESSANTS
• SUPPLEMENTAL OXYGEN AND PULMONARY REHABILITATION
• LUNG TRANSPLANTATION

Idiopathic Pulmonary 
Fibrosis
Idiopathic Pulmonary Fibrosis
chronic, progressive fibrosing interstitial pneumonia 
un-known cause
occurring primarily in older adults
Limited to the lungs
progressive worsening of dyspnea and lung function 
associated with a poor prognosis
Idiopathic Pulmonary Fibrosis
25% to 30% of ILDs
clinical, radiographic, physiologic, and pathologic 
diagnosis of exclusion 
prevalence    0.8 to 65/100,000 
Incidence       0.4 to 27/100,000 
increase markedly with age 
Clinical Features
IPF 
middle age 50 and 70 years of age
insidious onset of exertional breathlessness 
nonproductive cough
Constitutional symptoms are uncommon
weight loss, fever, fatigue, myalgias, or arthralgia 
symptoms for months to years before definitive evaluation  
12 to 18 months
physical examination
Bibasilar late inspiratory fine crackles (Velcro crackles) 
Clubbing of the fingers is seen in 40% to 75% late 
Cardiac examination is usually normal except in the middle or late 
Findings of pulmonary hypertension 
(e.g., augmented P2, right-sided lift, tricuspid regurgitation, and S3 gallop) 
Corpulmonale
Cyanosis late manifestation 
Spontaneous pneumothorax or pneumomediastinum is rare 
Blood and Serologic Studies
ESR
low-level ANA titer positivity (≥40 and <1 : 320)
 RF (>60 IU/mL) 
CBC diff counts are usually normal 
Chest Radiography
peripheral reticular opacities 
netlike appearance of linear or curvilinear densities
predominance at the lung bases 
A coarse reticular pattern or multiple cystic or honeycombed areas
correlate with advanced disease and poor prognosis 
diffuse bilateral lower lung predominant reticular opacities in 
a patient with idiopathic pulmonary fibrosis (IPF)
network of 2- to 3-mm cystic spaces is distributed 
throughout the lung fields. This patient with end-stage IPF
honeycomb lung
High-resolution CT image of 
advanced IPF shows
extensive honeycomb changes
cystic spaces 2 to 4 mm in diameter
HRCT scan 
 honeycomb cysts in a basilar subpleural distribution 
 variably sized cystic spaces in several layers
 Ground-glass opacities are common 
 Architectural distortion lung               fibrosis 
UIP
 typical clinical presentation and classic HRCT findings
 lung biopsy is unnecessary.
HRCT
 If honeycombing is absent on HRCT atypical features such as 
 ground-glass infiltrates
 lymphadenopathy, 
 nodules,
 air trapping 
 lung biopsy may be needed
Pulmonary function tests 
restrictive pattern
reduced DlCO
arterial hypoxemia
exaggerated or elicited by exercise 
Diagnosis
 Other potential causes of ILD, such as
 connective tissue disease
 hypersensitivity pneumonitis
 Asbestosis
 history, examination, & selected laboratory testing
Treatment 
No effective therapy for IPF
Thalidomide appears to improve cough 
GERD therapy
Antifbrotic drug: pirfenidone
Lung transplantation
Prednisone
Azathioprine
N-acetylcysteine (NAC) 
warfarin 
increase the risks of hospitalization and death

GRANULOMATOUS DISORDERS
INTERSTITIAL LUNG DISEASES WITH 
GRANULOMA FORMATION
Interstitial Lung Diseases with Granuloma Formation
granulomatosis with polyangiitis,
HP
chronic beryllium disease
sarcoidosis is the most common
Sarcoidosis
Defnition and Epidemiology
multisystem granulomatous disorder of unknown cause
lungs and thoracic lymph nodes 
Prevalence of 1 to 40 cases per 100,000 people worldwide
sarcoidosis may be asymptomatic
typically occurs in individuals between 10 and 40 years old
Noncaseating granulomas 
Pathology Sarcoidosis 
Epithelioid  
histiocytes
CD4+ T lymphocytes
Giant cells
lymphocytes
Connective tissue 
fibroblasts 
Subepithelial noncaseating granuloma
Sarcoidosis commonly involved
Upper respiratory system
Lymph nodes
Skin
Eyes    
Sarcoidosis
Virtually any other organ may be aﬀected
Liver
bone marrow
Spleen
musculoskeletal system
Heart
salivary glands
nervous system
Sarcoidosis
The granulomas may be clinically silent 
cause of these lesions is unknown
inhaled antigens ? 
Mycobacteria and Propionibacterium ?
Environmental substances ?
This inﬂammation may be self-limited
Sarcoidosis
Abnormal immune function
Cutaneous anergy
exhibited in lung by an CD4+/CD8+ T lymphocytes 
 pro-inﬂammatory cytokines 
Interferon γ
Interleukin 12
TNF α
immunomodulatory therapy, especially with INF α
immune reconstitution syndrome
Clinical Presentation
acute  
incidentally on routine CXR of asymptomatic individuals
Löfgren syndrome
Erythema nodosum
Fever
Arthritis
Hilar adenopathy
Uveoparotid fever (i.e., Heerfordt’s syndrome)
Uveitis
Parotitis
Facial nerve palsy
beter outcomes than for other clinical presentations of sarcoidosis
Clinical Presentation
vague and chronic
low-grade fevers
Fatigue 
night sweats
joint pains 
Clinical Presentation
Respiratory manifestations
one third to one half of patients
shortness of breath
Wheezing
dry cough
chest pain
Clinical Presentation
Skin manifestations 
erythema nodosum
Plaques
Nodules
lupus pernio
violaceous, disfguring, nodular lesion of the nose and cheeks  
Erythema nodosum
Clinical Presentation
Ocular symptoms 
Common
onset of uveitis may eventually lead to the diagnosis 
granulomatous extraocular organ involvement ?
Clinical Presentation
Neurosarcoidosis 
cranial nerve palsies 
headache in the seting of lymphocytic meningitis
Clinical Presentation
involve the heart 
Cardiomyopathy
Arrhythmias and sudden cardiac death 
conducting system by granulomatous infiltration  
Pulmonary hypertension 
pulmonary fibrosis 
Directly from granulomatous vasculitis
HILAR ADENOPATHY IN A PATIENT WITH
SARCOIDOSIS

Sarcoidosis with interstitial infltrates

SARCOIDOSIS
Pulmonary function tests show restriction or obstruction 
Liver involvement may cause mild elevation of AST & ALT 
cirrhosis and liver failure rare
Hypercalcemia and hypercalciuria
Kidney stones 
Elevated levels of ACE are common but are not specific
Diagnosis of sarcoidosis 
typical clinical, radiographic, and histologic picture 
diagnosis of exclusion 
Löfgren syndrome or uveoparotid fever may not require biopsy  
most patients require tissue biopsy of an aﬀected organ
noncaseating granulomas
ruling out other causes of granulomatous inﬂammation 
mycobacterial infection
Necrotizing granulomas

Diagnosis of sarcoidosis 
Bronchoscopy with TBLB are positive for 50% to 60% 
hemorrhage and pneumothorax
Endobronchial biopsies 
TBNA of mediastinal and hilar lymph nodes 
Endobronchial ultrasound guidance 
Diagnosis of sarcoidosis 
ophthalmologic evaluation 
24-hour collection of urine 
ECG & Holter monitoring 
If cardiac sarcoidosis is suspected
MRI or PET scanning
Treatment
Corticosteroids 
not cause symptoms or complications 
spontaneous remission
extrapulmonary organ involvement 
progressive pulmonary symptoms
20 to 40 mg per day may be initiated 
steroid-sparing agents
methotrexate
Inﬂiximab, an anti-TNF agent 
Treatment
erythema nodosum in the seting of Löfgren syndrome 
nonsteroidal anti-inﬂamatory
Other skin involvement 
hydroxychloroquine or topical corticosteroids
lupus pernio
inﬂiximab
anti-TNF agents 
extrapulmonary disease not responding to conventional therapy
Treatment
Anterior uveitis 
topical steroids
Other eye involvement 
systemic corticosteroids
cardiac sarcoidosis
systemic corticosteroids
Conduction system disease and arrhythmias 
placement of pacemakers or automatic ICD 
Neurosarcoidosis and hypercalcemia 
systemic steroid 
Prognosis
Spontaneous remission is common
death and disability occur rarely
acute sarcoidosis syndromes tend to remit and not recur
1/3 patients with sarcoidosis have chronic, progressive 
some patients develop pulmonary fibrosis or other EOD
Summary
Presents in many ways
Usually lungs
Any organ

